CA3107461A1 - Methods of treating overactive bladder using trospium - Google Patents

Methods of treating overactive bladder using trospium Download PDF

Info

Publication number
CA3107461A1
CA3107461A1 CA3107461A CA3107461A CA3107461A1 CA 3107461 A1 CA3107461 A1 CA 3107461A1 CA 3107461 A CA3107461 A CA 3107461A CA 3107461 A CA3107461 A CA 3107461A CA 3107461 A1 CA3107461 A1 CA 3107461A1
Authority
CA
Canada
Prior art keywords
trospium
bladder
individual
day
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3107461A
Other languages
English (en)
French (fr)
Inventor
Dennis GIESING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taris Biomedical LLC
Original Assignee
Taris Biomedical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical LLC filed Critical Taris Biomedical LLC
Publication of CA3107461A1 publication Critical patent/CA3107461A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0266—Shape memory materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CA3107461A 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium Pending CA3107461A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862713414P 2018-08-01 2018-08-01
US62/713,414 2018-08-01
US201962850481P 2019-05-20 2019-05-20
US62/850,481 2019-05-20
PCT/US2019/044478 WO2020028554A1 (en) 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium

Publications (1)

Publication Number Publication Date
CA3107461A1 true CA3107461A1 (en) 2020-02-06

Family

ID=69232612

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3107461A Pending CA3107461A1 (en) 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium

Country Status (10)

Country Link
US (2) US11464734B2 (enExample)
EP (1) EP3829582A4 (enExample)
JP (2) JP2021532155A (enExample)
KR (1) KR20210039403A (enExample)
CN (1) CN112839653A (enExample)
AU (1) AU2019315957A1 (enExample)
BR (1) BR112021001337A2 (enExample)
CA (1) CA3107461A1 (enExample)
MX (1) MX2021001264A (enExample)
WO (1) WO2020028554A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
KR20210039403A (ko) 2018-08-01 2021-04-09 타리스 바이오메디컬 엘엘씨 트로스피움을 사용한 과민성 방광의 치료 방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125696T3 (es) * 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
MX2013000002A (es) * 2001-07-27 2013-04-29 Teva Womens Health Inc Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva.
US20060058777A1 (en) 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
CA2513188A1 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
CA2552677A1 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
US20060128808A1 (en) * 2004-10-20 2006-06-15 Galderma Research & Development, S.N.C. Method of using adapalene in acne maintenance therapy
US20060217405A1 (en) 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
RU2435610C2 (ru) 2005-09-02 2011-12-10 Теравида, Инк. Терапия для лечения заболевания
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US9586035B2 (en) 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
AU2010265863C1 (en) 2009-06-26 2012-11-01 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
SMT202000670T1 (it) 2010-08-05 2021-01-05 Taris Biomedical Llc Dispositivo e kit di somministrazione di farmaci per stent ureterale
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
RU2598057C2 (ru) 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
SI2890384T1 (sl) * 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
SG11201502104YA (en) * 2012-09-18 2015-05-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
EP2719374A1 (en) 2012-10-12 2014-04-16 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Drug delivery device
EP2964310A1 (en) 2013-03-05 2016-01-13 TARIS Biomedical LLC Drug delivery devices and methods for controlled drug release through device orifice
HUE072250T2 (hu) 2013-03-15 2025-11-28 Taris Biomedical Llc Gyógyszeradagoló eszközök gyógyszeráteresztõ résszel
US9814671B2 (en) 2013-03-15 2017-11-14 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
ES2956840T3 (es) 2013-08-19 2023-12-29 Taris Biomedical Llc Dispositivos de administración de fármacos de múltiples unidades
CA2929554A1 (en) 2013-11-05 2015-05-14 Taris Biomedical Llc Osmotic drug delivery devices, kits, and methods
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
US10737078B2 (en) 2014-06-26 2020-08-11 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
EP3347036A1 (en) * 2015-09-10 2018-07-18 Assistance Publique - Hôpitaux de Paris Use of interleukin 2 for treating spondyloarthritis
JP6283440B1 (ja) * 2016-10-27 2018-02-21 Ｅａファーマ株式会社 逆流性食道炎の再発抑制剤
SMT202100310T1 (it) 2017-02-01 2021-07-12 Taris Biomedical Llc Dispositivi per la deposizione di farmaci in vivo
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
KR20210039403A (ko) 2018-08-01 2021-04-09 타리스 바이오메디컬 엘엘씨 트로스피움을 사용한 과민성 방광의 치료 방법

Also Published As

Publication number Publication date
AU2019315957A1 (en) 2021-02-18
EP3829582A4 (en) 2022-04-27
MX2021001264A (es) 2021-07-02
CN112839653A (zh) 2021-05-25
BR112021001337A2 (pt) 2021-04-20
US20230075003A1 (en) 2023-03-09
US12133913B2 (en) 2024-11-05
JP2024164020A (ja) 2024-11-26
WO2020028554A1 (en) 2020-02-06
KR20210039403A (ko) 2021-04-09
JP2021532155A (ja) 2021-11-25
US11464734B2 (en) 2022-10-11
EP3829582A1 (en) 2021-06-09
US20200060966A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US12133913B2 (en) Methods of treating overactive bladder using trospium
US11850244B2 (en) Drug delivery systems and methods for treatment of bladder dysfunction or disorder using trospium
RU2620032C2 (ru) Схема приема лидокаина для применения в продолжительном лечении боли в мочевом пузыре и раздражения при мочеиспускании
CA2882319C (en) Drug delivery systems and methods for treatment of bladder cancer comprisingioxaliplatin
EP3113782B1 (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
CN112516154A (zh) 用于治疗前列腺的药物递送系统和方法
JP7860691B2 (ja) ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法
RU2832085C2 (ru) Способы лечения гиперактивного мочевого пузыря с применением троспия хлорида
BR122025013571A2 (pt) Usos de trópsio no tratamento de bexiga hiperativa e dispositivos intravesicais
HK40026424A (en) Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
HK40042011A (en) Drug delivery systems and methods for treatment of prostate
EA045084B1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240830

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250116

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250116

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260609

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260609